Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Catamaran Bio Launches with $42M in Series A

2020-11-23
CAMBRIDGE, MA, Catamaran Bio has launched with $42 million in Series A financing co-led by Sofinnova Partners and Lightstone Ventures.
Catamaran Bio, a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, has launched with $42 million in financing. Sofinnova Partners and Lightstone Ventures co-led the Series A round that is part of the launch financing, with participation by founding investor SV Health Investors, as well as Takeda Ventures and Astellas Venture Management.

Catamaran Bio is developing novel, off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers, including solid tumors. Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors